A Phase 1, Randomized, Double-Masked, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral QA102 in Healthy Young and Older Adult Subjects
Latest Information Update: 18 Jan 2022
At a glance
- Drugs QA 102 (Primary)
- Indications Age-related macular degeneration
- Focus Adverse reactions
- Sponsors Zhuhai Qiwei Biotechnology
- 31 Dec 2021 Status changed from recruiting to completed.
- 24 Sep 2021 New trial record